Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment https://www.biorxiv.org/content/10.1101/2023.06.22.544406v1?med=mas
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment https://www.biorxiv.org/content/10.1101/2023.06.22.544406v1?med=mas